Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
about
Incretin-Based Therapy for Prevention of Diabetic Vascular ComplicationsVascular repair strategies in type 2 diabetes: novel insightsDeciding oral drugs after metformin in type 2 diabetes: An evidence-based approachThe short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United StatesDipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemClinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes.Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in TaiwanTwo-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control studyCardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular eventsDipeptidyl Peptidase-4 Inhibitor Alarms: Is Heart Failure Caused by a Class Effect?Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study.Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1.Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness EvaluatThe clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management.Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.A review of gliptins for 2014.DPP-4 inhibitors: focus on safety.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.Alogliptin: a review of its use in patients with type 2 diabetes mellitus.Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.Sitagliptin for Type 2 diabetes: a 2015 update.Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS.The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?Sitagliptin: A Review in Type 2 Diabetes.Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease.Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
P2860
Q26765470-0BE2350B-B57F-400A-B8CA-1AA8ED0B75A9Q26778658-4C1DDF05-C79E-4605-B8FC-EE8205E21024Q26851797-9F9FEACA-AB66-4C1B-9D2D-DFF90EEC11B2Q28545766-0CB01B97-6B54-48EA-8219-C2A6122AB354Q30846870-DC5552C6-434D-4869-88B0-521843691B87Q34062829-046524E8-6771-453C-AB1C-2435D3C45B71Q34620565-620EE530-0698-4688-9B51-5C11E8D11897Q35675678-67119A24-C422-4AB7-8AC7-C3D7F8963600Q35681641-DA414CD9-4AF4-48B6-8CFF-51FE33FB4989Q35691976-4E704FEF-8571-4965-87D2-1E812EEA4DB0Q35736564-E8F565D8-F3A2-4C6A-A87C-00E7BE435A35Q35790625-E1B331AE-6908-4483-8EB7-47476C9B4C63Q36196539-E9C2729F-077A-441A-B88A-6A450A8A18ABQ37008619-A593EDC1-A966-4249-AEE9-9D18E2DCEC04Q37517909-BEA15F03-3F41-4170-95B5-59E6D58BD958Q37681515-C90C559D-846E-4143-B116-37CCBCCDD101Q38246002-0FA3B47D-6B08-486B-A3E2-B40535F42ACBQ38258938-2499511B-8A76-492D-873E-67F8404B0CE7Q38266290-7BD54BC6-7271-4943-8DD6-725B3D344BB6Q38285608-C0081F9A-B810-4594-A329-EB7E1ACAD6BBQ38335751-7659E525-2BDE-4078-8E3F-A712D9921AEDQ38371242-D5F0375C-B8A9-4F1D-B449-2C42208DF4D2Q38410742-C4494296-DCD0-4A0F-A800-57CF261233E0Q38412153-2F80516F-294D-493D-BE23-91F5ACA76CE2Q38468017-E3E3D65F-E644-4533-8444-766A5FA7DAE7Q38497683-57E70B2F-4016-4541-A685-21E5000144CDQ38663559-CBAD5CCF-CABD-4FC2-B1C5-5E159A06F147Q38885733-338ED59F-FB52-4D8D-9BDC-60DB1A6532F2Q38931845-CA628F1F-340B-4090-85A3-45EAC8E9CF91Q39081543-B6B8BE1C-6EC4-4E08-804A-0E43D8E0B6C6Q39410329-F13ECB00-6BBC-452D-A9CB-2BB1EAB26F31Q41740997-0C26F26F-CD51-4C8E-8F25-0420BE2B72FFQ42175983-6AA15546-44CF-4959-9191-5BED4A1E529EQ44061187-09589C6E-16D8-45BB-8A4C-58AE17376057Q47580956-A50B58E5-0301-4EC0-9957-A76696D96792Q47745744-64764BF2-FDC5-48EC-8153-B2A17348EFE0Q48043450-065F3F41-4295-4DB8-A400-884EF20BD4F0Q48245548-234B84AB-7E1B-4A7D-930E-EDA3C8EDDB09Q48632120-A85D48ED-C725-4BB0-B39E-B8AA920C25FEQ50102788-C34BF45D-C487-4725-9801-0E627774AAEF
P2860
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Rationale, design, and organiz ...... lished cardiovascular disease.
@en
Rationale, design, and organiz ...... lished cardiovascular disease.
@nl
type
label
Rationale, design, and organiz ...... lished cardiovascular disease.
@en
Rationale, design, and organiz ...... lished cardiovascular disease.
@nl
prefLabel
Rationale, design, and organiz ...... lished cardiovascular disease.
@en
Rationale, design, and organiz ...... lished cardiovascular disease.
@nl
P2093
P50
P921
P1476
Rationale, design, and organiz ...... blished cardiovascular disease
@en
P2093
Deborah R Shapiro
Jennifer B Green
Keith D Kaufman
Robert M Califf
P304
983-989.e7
P356
10.1016/J.AHJ.2013.09.003
P407
P577
2013-10-23T00:00:00Z